Sandoz Group AG (SDZ SW) stock market data APIs
CHF32.5802
-0.03(-0.1%)
as of April 17, 2025
Sandoz Group AG Financial Data Overview
Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, diabetes, immunology, endocrinology, hematology, and ophthalmology. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. The company was founded in 1886 and is headquartered in Basel, Switzerland.
Prev. Close
32.5802
Open
32.5499
High
32.5802
Low
31.7939
52 wk Range
25.7736-44.2815
Market Cap
14 011 M
P/E Ratio
0
Shares Outstanding
431 M
Revenue
10 384 M
Dividends (Yield)
0.0184
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Sandoz Group AG data using free add-ons & libraries
Get Sandoz Group AG Fundamental Data
Sandoz Group AG Fundamental data includes:
- Net Revenue: 10 384 M
- EBITDA: 734 M
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Sandoz Group AG News
New
Shareholders approve all resolutions proposed by Board of Directors at Annual General Meeting of Sandoz Group AG
Sandoz Group All proposals of Board of Directors approved Gilbert Ghostine re-elected as Chairman of Board of Directors; all other Board members standing for re-election confirmed Dividend of CHF 0...
![[Corrected] Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US](https://eodhd.com/build/assets/fallback9-BX8j0yAz.jpg)
[Corrected] Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US
Sandoz Group Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules – corrected: reference to date of product launch in Europe removed; link to “Important Safety Information” ...
Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US
Sandoz Group Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Company aims to accelerate access to much-needed biosimilar to reference medicine Enbrel®* for US patients with...
Sandoz strengthens its balance sheet by issuing new bonds to repay spin-off term loans, and signs new USD 2 billion revolving credit facility
Sandoz Group MEDIA RELEASE NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN New USD 2.0 billion multi-currency revolving credit facility (RCF) in place to further stren...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
